IBRX Stock ImmunityBio (IBRX, $2.1) entered Downtrend as Momentum indicator drops below 0 level on Dec 23, 2025

GET DAILY SIGNALS

Get AI intraday signals

IBRX - ImmunityBio

Momentum signal

View

Odds of DOWN Trend

Price: $2.1

Daily change: -$0.17 (-7.49%)

Daily volume: 15M

Capitalization: $2.1B

Industry: Biotechnology

This indicator may be signaling that IBRX's price has further to drop, since it fell below its price logged 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options. A.I.dvisor backtested 97 similar cases where IBRX's Momentum Indicator fell below the 0 level, and of them led to a successful outcome. Odds of Success:

Momentum Indicator for IBRX turns negative, indicating new downward trend

IBRX saw its Momentum Indicator move below the 0 level on December 23, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 97 similar instances where the indicator turned negative. In of the 97 cases, the stock moved further down in the following days. The odds of a decline are at .

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for IBRX turned negative on December 17, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at .

IBRX moved below its 50-day moving average on December 23, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

IBRX broke above its upper Bollinger Band on November 28, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 69 cases where IBRX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where IBRX advanced for three days, in of 243 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 116 cases where IBRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (26.541). P/E Ratio (0.000) is within average values for comparable stocks, (51.479). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.873). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (22.173) is also within normal values, averaging (311.015).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. IBRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IBRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.